Tony Shum, Chairman of Cardima, said, "The past year has brought tremendouspositive changes to the Company and this transaction marks anothersignificant step towards building the New Cardima. We thank ourshareholders for their continued support, which allows us to continue thesystematic commercialization of our great range of products. This loanfacility provides important resources as we begin to rapidly expand thenumber and scope of our distributor relationships around the world and planfor exciting and dynamic growth in 2009."

About Cardima

Cardima, Inc. has developed the PATHFINDER®, TRACER(TM) and REVELATION®Series of diagnostic catheters, the VUEPORT® and NAVIPORT® Series ofguiding catheters, the INTELLITEMP® Energy Management Device, and theSurgical Ablation System (SAS). All of these devices are CE marked andreceived U.S. FDA 510(k) clearance. The REVELATION® Series of ablationcatheters with the INTELLITEMP® EP Energy Management Device was developedand marketed for the treatment of atrial fibrillation (AF) after receivingCE mark approval in Europe; it is not currently available in the U.S.

PATHFINDER®, TRACER™, VUEPORT®, NAVIPORT®, REVELATION® andINTELLITEMP® are registered trademarks of Cardima, Inc.

For more information, please visit the Company's website atwww.cardima.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statementsare subject to risks and uncertainties. Investors are referred to the fulldiscussion of risks and uncertainties associated with forward-lookingstatements as contained in our reports to the Securities and ExchangeCommission, including our Forms 10-K and 10-Q. The Company assumes noobligation to update the forward-looking information.

Contact:Dr. Richard GastonCardima, Inc.(510) 354-0300http://www.Cardima.com